type="text/javascript" charset="utf-8">
Step 1 Of 3
Tesamorelin | Ipamorelin | |
Primary mechanism | A synthetic analogue of growth hormone-releasing hormone (GHRH). | A synthetic pentapeptide that mimics the hormone ghrelin. |
Receptor target | Binds to GHRH receptors in the pituitary gland. | Binds to ghrelin/GH secretagogue receptors in the pituitary and other tissues. |
Targeted fat reduction | Specifically targets and reduces visceral adipose tissue (VAT) or deep belly fat. | Contributes to overall fat loss rather than being specifically targeted toward visceral fat. |
Primary therapeutic use | Medically approved for treating HIV-associated lipodystrophy. | Used off-label for anti-aging, improved recovery, and general wellness. |
Effect on other hormones | Can cause mild, transient increases in blood sugar. | Does not significantly increase cortisol or prolactin levels. |
Result profile | Produces a more pronounced and targeted increase in GH and IGF-1 levels. | Creates a more gradual and consistent release of GH. |
Side effect profile | Moderate, including potential joint pain, water retention, and minor blood sugar increases. | Low, and is generally well-tolerated. |